Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4047 - Hepatitis B and C reactivation rates due to cytotoxic chemotherapy in patients with solid tumors

Date

10 Sep 2017

Session

Poster display session

Topics

Supportive Care and Symptom Management;  Therapy

Presenters

Mustafa Karaca

Citation

Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388

Authors

M. Karaca1, D. Tural2, I. Cil2, G. Ozet3, O.K. Yucel4, A. Ozet1

Author affiliations

  • 1 Department Of Medical Oncology, Gazi University Medical School, 6500 - Ankara/TR
  • 2 Department Of Medical Oncology, Istanbul Bakirkoy Dr Sadi Konuk Education and Research Hospital, 34147 - Istanbul/TR
  • 3 Department Of Haematology, Yildirim Beyazit University, Ankara/TR
  • 4 Department Of Haematology, Akdeniz University, Antalya/TR
More

Resources

Abstract 4047

Background

We tried to determine the incidence of the reactivation rates of chronic HBV and HCV infections in cancer patients who received different types of chemotherapy or immunosuppressive therapy. Also we tried to identify the chemotherapy regimens though to be associated with this reactivation of chronic HBV and HCV infections.

Methods

Between 2000 and 2014, 8322 cancer patients who were admitted to oncology departments were evaluated retrospectively and 3890 patients in whom hepatitis serology were available were included in this study. Their mortality rates, chemotherapy regimens, cancer types, number of positive hepatitis serology and reactivation rates were also obtained.

Results

In all 8322 cancer patients, only 3890 (47%) patients had hepatitis serology results and 355 patients had positive hepatitis serology results (HBsAg, anti-HBcAg, anti-HCV). Of them, 4.24% had anti-HBcAg positivity, 3.65%had HBsAg positivity, and 1.23% had anti-HCV positivity. Nineteen patients with HBsAg positive (13.38%), 4 patients with anti-HBcAg positive (2.42%), and 2 patients with anti-HCV positive (4.16%) had reactivation. hepatitis reactivation was seen significantly higher in lymphoma patients (p = 0.032). Reactivation rate of hepatitis B in those patients (HBsAg positive) was detected as 57.14%. In patients with hepatitis reactivation, the rates of usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine were determined as significantly higher than patients with positive hepatitis serology results but without hepatitis reactivation (p > 0.05 for all).

Conclusions

An association between hepatitis reactivation and the usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine was detected. Thus physicians should consider antiviral prophylaxis before initiating these chemotherapeutics.

Clinical trial identification

Legal entity responsible for the study

Individuals: Ahmet Ozet, Deniz Tural

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.